{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:04:58Z","timestamp":1793325898171,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T00:00:00Z","timestamp":1617494400000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31870873"],"award-info":[{"award-number":["31870873"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31991171"],"award-info":[{"award-number":["31991171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803071"],"award-info":[{"award-number":["81803071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830002"],"award-info":[{"award-number":["81830002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872479"],"award-info":[{"award-number":["81872479"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903153"],"award-info":[{"award-number":["81903153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82022057"],"award-info":[{"award-number":["82022057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese PLA General Hospital\u2019s National Excellent Young Scholar Science","award":["2017-YQPY-2017, 2020-JQPY-001"],"award-info":[{"award-number":["2017-YQPY-2017, 2020-JQPY-001"]}]},{"name":"National Key Research and Development Program of China","award":["2019YFC1316205 to JN"],"award-info":[{"award-number":["2019YFC1316205 to JN"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,3,9]]},"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed\/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating agent, decitabine, improves progression-free survival (PFS) in patients with relapsed\/refractory cHL over camrelizumab alone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This extended follow-up of an ongoing randomized phase II trial analyzed PFS among patients enrolled from January 2017 through July 2018. Sixty-one patients with relapsed\/refractory cHL who were clinically na\u00efve to PD-1 blockade and had received \u22652 previous therapies were randomized 1:2 to receive either camrelizumab (200\u2009mg) monotherapy or camrelizumab (200\u2009mg, day 8) combined with decitabine (10\u2009mg\/day, days 1\u20135) every 3 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>With a median follow-up of 34.5 months, complete remission was 79% (95% CI 63% to 90%) in the decitabine-plus-camrelizumab group versus 32% (95% CI 13% to 57%) in the camrelizumab group (p=0.001). Median duration of response was not reached in the decitabine-plus-camrelizumab group, with an estimated 63% (95% CI 46% to 75%) of patients maintaining a response at 24 months. Median PFS with decitabine-plus-camrelizumab therapy was 35.0 months (95%\u2009CI not reached) and 15.5 months (95%\u2009CI 8.4 to 22.7 months) with camrelizumab monotherapy (HR, 0.46; 95%\u2009CI 0.21 to 1.01; p=0.02). Female gender, lower tumor burden, and fewer previous therapies were favorable prognostic factors for durable remission with camrelizumab monotherapy. The PFS benefits of decitabine-plus-camrelizumab versus camrelizumab were observed in most subgroups, especially in patients with relative larger tumor burdens and those treated with \u22653 prior therapies. After decitabine-plus-camrelizumab treatment, the percentage increase of circulating peripheral central memory T-cells correlated with both improved clinical response and PFS, suggesting a putative biomarker of decitabine-plus-camrelizumab therapy for cHL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Decitabine-plus-camrelizumab results in longer PFS compared with camrelizumab alone in patients with relapsed\/refractory cHL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02961101\">NCT02961101<\/jats:ext-link> and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03250962\">NCT03250962<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-002347","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:31:51Z","timestamp":1617622311000},"page":"e002347","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":71,"title":["Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02961101","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03250962","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02684292","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03138499","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Brock","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Statistics and Epidemiology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-3899","authenticated-orcid":false,"given":"Weidong","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Bio-therapeutic, the First Medical Centre, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"2025100313470311000_9.4.e002347.1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100313470311000_9.4.e002347.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"2025100313470311000_9.4.e002347.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"2025100313470311000_9.4.e002347.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"2025100313470311000_9.4.e002347.5","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025100313470311000_9.4.e002347.6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025100313470311000_9.4.e002347.7","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/bloodadvances.2019001367","article-title":"KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"4","author":"Armand","year":"2020","journal-title":"Blood Adv"},{"key":"2025100313470311000_9.4.e002347.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"2025100313470311000_9.4.e002347.9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438"},{"key":"2025100313470311000_9.4.e002347.10","first-page":"213","article-title":"Where does PD-1 blockade fit in HL therapy?","volume":"2018","author":"Herrera","year":"2018","journal-title":"Hematol-Am Soc Hemat"},{"key":"2025100313470311000_9.4.e002347.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215"},{"key":"2025100313470311000_9.4.e002347.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"2025100313470311000_9.4.e002347.13","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025100313470311000_9.4.e002347.14","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody Camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100313470311000_9.4.e002347.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2025100313470311000_9.4.e002347.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"2025100313470311000_9.4.e002347.17","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to Immune-Checkpoint blockade in cancer: tumor-intrinsic and -Extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"2025100313470311000_9.4.e002347.18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 Blockade-Mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"2025100313470311000_9.4.e002347.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807"},{"key":"2025100313470311000_9.4.e002347.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.956"},{"key":"2025100313470311000_9.4.e002347.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3909"},{"key":"2025100313470311000_9.4.e002347.22","first-page":"1","article-title":"Low-Dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I\/II report","volume":"2014","author":"Fan","year":"2014","journal-title":"J Immunol Res"},{"key":"2025100313470311000_9.4.e002347.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.110890"},{"key":"2025100313470311000_9.4.e002347.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2025100313470311000_9.4.e002347.25","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025100313470311000_9.4.e002347.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-772681"},{"key":"2025100313470311000_9.4.e002347.27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi119"},{"key":"2025100313470311000_9.4.e002347.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00205-2"},{"key":"2025100313470311000_9.4.e002347.29","doi-asserted-by":"publisher","DOI":"10.1038\/nature22367"},{"key":"2025100313470311000_9.4.e002347.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1836-5"},{"key":"2025100313470311000_9.4.e002347.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6"},{"key":"2025100313470311000_9.4.e002347.32","doi-asserted-by":"publisher","DOI":"10.1038\/nm0116-8"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:47:08Z","timestamp":1759524428000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,5]]},"published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1136\/jitc-2021-002347"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002347","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}